Billy J Hudson

US Patent:

7122517, Oct 17, 2006

Filed:

Jul 26, 2002

Appl. No.:

10/206699

Inventors:

Billy G. Hudson - Nashville TN, US
Munirathinam Sundaramoorthy - Nashville TN, US

Assignee:

Kansas University Medical Center - Kansas City KS

International Classification:

A61K 38/00
A61K 38/08
A61K 38/10

US Classification:

514 4, 530326, 530327, 530328

Abstract:

The present invention provides a crystallized NC1 domain hexamer of Type IV collagen, and methods for making the crystal, wherein the NC1 domain hexamer is crystallized such that the three dimensional structure of the crystallized NC1 domain hexamer can be determined to a resolution of at least 3 Å or better. The present invention also provides a method for designing compounds to inhibit angiogenesis, tumor growth, tumor metastasis, endothelial cell adhesion and/or proliferation, and/or basal lamina assembly, comprising analyzing the three dimensional structure of a crystallized Type IV collagen NC1 domain hexamer produced by the methods of the invention, and identifying and synthesizing compounds that target regions of the NC1 domain that have been identified by the analysis as being important for type IV collagen heterotrimer and hexamer assembly. The present invention also provides novel polypeptides designed by the rational drug design methods of the present invention, based on an analysis of the type TV collagen NC1 hexamer structure disclosed herein.

US Patent:

20040132662, Jul 8, 2004

Filed:

Dec 17, 2003

Appl. No.:

10/738304

Inventors:

Billy Hudson - Nashville TN, US
Michael Sarras - Kansas City KS, US

Assignee:

Kansas University Medical Center

International Classification:

A61K038/39

US Classification:

514/012000

Abstract:

The instant invention provides methods and kits for inhibiting angiogenesis, tumor growth and metastasis, and endothelial cell interactions with the extracellular matrix, involving contacting the tumor or animal tissue with at least one isolated type IV collagen NCl chain monomer. In a specific embodiment of the invention, the isolated domain of type IV collagen comprises the NCl (1), (2), (3), or (6) chain monomer, or protein constructs having substantially the same structure as the NCl (1), (2), (3), or (6) chain monomer.

US Patent:

20050004033, Jan 6, 2005

Filed:

Jul 30, 2004

Appl. No.:

10/903827

Inventors:

Billy Hudson - Nashville TN, US
Michael Sarras - Kansas City KS, US

International Classification:

A61K038/39

US Classification:

514012000

Abstract:

The instant invention provides methods and kits for inhibiting angiogenesis, tumor growth and metastasis, and endothelial cell interactions with the extracellular matrix, involving contacting the tumor or animal tissue with at least one isolated type IV collagen NC1 α chain monomer. In a specific embodiment of the invention, the isolated domain of type IV collagen comprises the NC1 (α1), (α2), (α3), or (α6) chain monomer, or protein constructs having substantially the same structure as the NC1 (α1), (α2), (α3), or (α6) chain monomer.

US Patent:

20070042965, Feb 22, 2007

Filed:

Sep 19, 2006

Appl. No.:

11/523425

Inventors:

Billy Hudson - Nashville TN, US
Munirathinam Sundaramoorthy - Nashville TN, US

International Classification:

A61K 38/08
C07K 7/06

US Classification:

514016000, 530329000

Abstract:

The present invention provides a crystallized NC1 domain hexamer of Type IV collagen, and methods for making the crystal, wherein the NC1 domain hexamer is crystallized such that the three dimensional structure of the crystallized NC1 domain hexamer can be determined to a resolution of at least 3 Å or better. The present invention also provides a method for designing compounds to inhibit angiogenesis, tumor growth, tumor metastasis, endothelial cell adhesion and/or proliferation, and/or basal lamina assembly, comprising analyzing the three dimensional structure of a crystallized Type IV collagen NC1 domain hexamer produced by the methods of the invention, and identifying and synthesizing compounds that target regions of the NC1 domain that have been identified by the analysis as being important for type IV collagen heterotrimer and hexamer assembly. The present invention also provides novel polypeptides designed by the rational drug design methods of the present invention, based on an analysis of the type IV collagen NC1 hexamer structure disclosed herein.

US Patent:

20070238761, Oct 11, 2007

Filed:

Oct 31, 2006

Appl. No.:

11/590679

Inventors:

Billy Hudson - Brentwood TN, US
Paul Voziyan - Nolensville TN, US
Alp Ikizler - Nashville TN, US

International Classification:

A61K 31/4412
A61P 13/12

US Classification:

514351000

Abstract:

Methods for treating and/or preventing at least one symptom of a disorder associated with oxidative stress, carbonyl stress, or combinations thereof in a subject. In some embodiments, the methods include administering to the subject an effective amount of pyridoxamine, an analog or derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing. Also provided are methods for treating or preventing a nephropathy, acute renal injury, acute renal failure, or combinations thereof in a subject, and formulations adapted for intravenous administration comprising pyridoxamine, an analog or derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing.

US Patent:

20090221650, Sep 3, 2009

Filed:

Feb 29, 2008

Appl. No.:

12/040627

Inventors:

Billy G. Hudson - Brentwood TN, US
Paul Voziyan - Nolensville TN, US
Alp Ikizler - Nashville TN, US

International Classification:

A61K 31/4412
A61P 13/12

US Classification:

514351

Abstract:

Methods for treating and/or preventing at least one symptom of a disorder associated with oxidative stress, carbonyl stress, or combinations thereof in a subject. In some embodiments, the methods include administering to the subject an effective amount of pyridoxamine, an analog or derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing. Also provided are methods for treating or preventing a nephropathy, acute renal injury, acute renal failure, or combinations thereof in a subject, and formulations adapted for intravenous administration comprising pyridoxamine, an analog or derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing.

US Patent:

20100240710, Sep 23, 2010

Filed:

May 7, 2010

Appl. No.:

12/775641

Inventors:

Billy G. Hudson - Brentwood TN, US
Paul Voziyan - Nolensville TN, US
Alp Ikizler - Nashville TN, US

Assignee:

Vanderbilt University - Nashville TN

International Classification:

A61K 31/44
A61P 13/12
C07D 211/72

US Classification:

514351, 546300

Abstract:

Methods for treating and/or preventing at least one symptom of a disorder associated with oxidative stress, carbonyl stress, or combinations thereof in a subject. In some embodiments, the methods include administering to the subject an effective amount of pyridoxamine, an analog or derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing. Also provided are methods for treating or preventing a nephropathy, acute renal injury, acute renal failure, or combinations thereof in a subject, and formulations adapted for intravenous administration comprising pyridoxamine, an analog or derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing.

US Patent:

20120177656, Jul 12, 2012

Filed:

Jun 11, 2010

Appl. No.:

13/376687

Inventors:

Billy G. Hudson - Brentwood TN, US
Roberto Vanacore - Nashville TN, US
Gautam Bhave - Nashville TN, US
Vadim Pedchenko - Nolensville TN, US

International Classification:

A61K 39/395
A61K 31/05
A61P 33/10
A61K 31/713
A61K 31/7105
A61P 35/00
A61K 31/4164
A61K 38/44

US Classification:

4241461, 514392, 514731, 424 944, 514 44 A, 514 44 R

Abstract:

Methods for regulating the formation of a sulfilimine crosslink in a subject by administering a sulfilimine crosslink modulator are disclosed The sulfilimine modulator may inhibit or create a sulfilimine crosslink and maybe useful for treating a disease, such as cancer The sulfilimine crosslink may be between two or more peptides